Celularity Balance Sheet Health
Financial Health criteria checks 2/6
Celularity has a total shareholder equity of $30.2M and total debt of $35.0M, which brings its debt-to-equity ratio to 115.7%. Its total assets and total liabilities are $157.2M and $126.9M respectively.
Key information
115.7%
Debt to equity ratio
US$35.00m
Debt
| Interest coverage ratio | n/a |
| Cash | US$273.00k |
| Equity | US$30.25m |
| Total liabilities | US$126.95m |
| Total assets | US$157.19m |
Recent financial health updates
Recent updates
Celularity Inc. (NASDAQ:CELU) Held Back By Insufficient Growth Even After Shares Climb 80%
Feb 14
Celularity appoints Adrian Kilcoyne as chief medical officer
Oct 03Celularity falls after announcing fund raising deal
Sep 15Celularity falls 10% on deal for $150M common stock offering
Sep 08Celularity begins phase 1/2a trial for cell therapy CYNK-101 to treat cancers
Jul 27News Flash: Analysts Just Made A Massive Upgrade To Their Celularity Inc. (NASDAQ:CELU) Forecasts
Dec 14Celularity: Celgene Spin-Off Developing Allogeneic Therapies
Sep 06Financial Position Analysis
Short Term Liabilities: CELU's short term assets ($16.5M) do not cover its short term liabilities ($84.6M).
Long Term Liabilities: CELU's short term assets ($16.5M) do not cover its long term liabilities ($42.3M).
Debt to Equity History and Analysis
Debt Level: CELU's net debt to equity ratio (114.8%) is considered high.
Reducing Debt: Insufficient data to determine if CELU's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CELU has sufficient cash runway for 0 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: CELU is forecast to have sufficient cash runway for 0 months based on free cash flow estimates, but has since raised additional capital.